Corynebacterium jeikeium

Bacteria
General | Carbohydrate O/F | Substrate utilisation | Enzymes | Metabolites | Antibiotics

Overview

  • Corynebacterium jeikeium is a Gram-positive, non-spore-forming, aerobic, non-motile, pallasades bacterium. It has been detected in at least 1 gut microbiome compilation study or metastudy. The DNA G+C content is 58-61%. Corynebacterium jeikeium is probably a rare gut coloniser.



  • This organism has been recovered from clinical specimens (bone marrow, blood, skin, urine, heart valve). The risk classification (www.baua.de) for this organism is 2, i.e., risk of individual infection, but low risk of spread. It is an opportunistic pathogen. It's gut microbiome symbiotic status is unknown.
    • GENERAL CHARACTERISTICS
    Character Response
  • 🌡
  • Temperature tolerance:
  • grows at 30℃; grows at 37℃; grows at 42℃;
  • H+
  • Acid from carbohydrates usually produced:
  • galactose; glucose;
  • ±
  • Strain-dependent acid from carbs:
  • maltose;
  • Active enzymes:
  • catalase; esterase; Leu arylamidase; Leu-Gly arylamidase;
    • SPECIAL FEATURES
    Character Response
  • ✗
  • Metabolites not produced:
  • Hâ‚‚S; indole;
  • ✗
  • Methyl red test:
  • not active
  • ✗
  • VP test:
  • not active
  • ✗
  • Haemolysis:
  • absent
  • ✗
  • Nitrate:
  • not reduced
    • RESPONSE TO ANTIBIOTICS (Tyrrell2012); (Goldstein2008); (Goldstein2006a); (Goldstein2006b); (Goldstein2000);
    Class Active Resistant
  • Penicillins:
  • penicillin G;
  • amoxicillin-clavulanic acid; ampicillin; ampicillin-sulbactam; imipenem; penicillin; piperacillin-tazobactam;
  • Cephalosporins:
  • cefotetan; ceftazidime;
  • Macrolides:
  • azithromycin; erythromycin; quinupristin-dalfopristin;
  • Tetracyclines:
  • doxycycline; minocycline; tetracycline; tigecycline;
  • Quinolines:
  • moxifloxacin;
  • levofloxacin;
  • Vancomycins:
  • vancomycin; dalbavancin;
  • Miscellaneous antibiotics:
  • daptomycin; linezolid;
  • clindamycin;

    • Details

    GENERAL
    Lineage Physiology General Growth Tolerances Hydrol./digest./degr.
    Phylum:  Actinobacteria Class:  Actinomycetia Order:  Corynebacteriales Family:  Corynebacteriaceae Genus:  Corynebacterium Gram stain:  + O2 Relation.:  aerobic Spore:  No spore Motility:  Sessile Morphology:  Pallasades
    Health:  Unknown
    Source:  clinical specimens (bone marrow, blood, skin, urine, heart valve)
    DNA G+C(%):  58-61
    Lower T(℃):  30(+)
    Mid T(℃):  37(+)
    High T(℃):  42(+)
    		Aesculin:  neg Urea:  neg Gelatin:  neg Starch:  neg Casein:  neg Tyrosine:  neg Tween:  20(+) 40(neg) 60(neg) 80(+)
    CARBOHYDRATE ACID FORMATION
    Monosaccharide O/F Oligosaccharide O/F Polysaccharide O/F Polyol O/F Other O/F
    Arabinose:  neg Fructose:  neg Galactose:  + Glucose:  + Rhamnose:  neg Sorbose:  neg Cellubiose:  neg Lactose:  neg Maltose:  d Melibiose:  neg Sucrose:  neg Trehalose:  neg Dextrin:  neg Glycogen:  neg Adonitol:  neg Dulcitol:  neg Erythritol:  neg Glycerol:  neg Inositol:  neg Mannitol:  neg Salicin:  neg
    SUBSTRATE ASSIMILATION & UTILISATION
    Monosaccharide util/assim Oligosaccharide util/assim Other carboh. util/assim Amino acid util/assim Organic acid util/assim
    Citrate:  neg
    ENZYME ACTIVITY
    Enzymes: General Enzymes: Carbohydrate Enzymes: Protein Enzymes: Arylamidases Enzymes: Esters/fats
    Catalase:  + Ac-β-glcamnd:  neg β-Galactosidase:  neg α-Glucosidase:  neg β-Glucosidase:  neg ArgDH:  neg LysDC:  neg OrnDC:  neg LeuAA:  + LeuGlyAA:  + ProAA:  neg PyrrolidAA:  neg Esterase:  +
    METABOLITES - PRODUCTION & USE
    Fuel Usable Metabolites Metabolites Released Special Products Compounds Produced

    		H2S:  neg Indole:  neg
    ANTIBIOTICS ℞
    Penicillins & Penems (μg/mL) Cephalosporins (μg/mL) Aminoglycosides (μg/mL) Macrolides (μg/mL) Quinolones (μg/mL)
    Augmentin:  R(MIC50): >8, MIC90: >8, RNG: (0.06–>8)
    ampicillin:  R(MIC50): >32, MIC90: >32, RNG: (>32->32)
    amp-sulb:  R(MIC50): >64, MIC90: >64, RNG: (1–>64)
    penicillin:  R(MIC50): >8, MIC90: >8, RNG: (0.06–>8)
    penicillin_G:  S(MIC50): 1, MIC90: 1, RNG: (0.125–1)
    piper-taz:  R(MIC50): >128, MIC90: >128, RNG: (64->128)
    doripenem:  Var(MIC50): 1, MIC90: 8, RNG: (0.25–>32)
    ertapenem:  Var(MIC50): 1, MIC90: 32, RNG: (0.5–>32)
    imipenem:  R(MIC50): >32, MIC90: >32, RNG: (1->32)
    meropenem:  Var(MIC50): 0.25, MIC90: >8, RNG: (0.06–>8)
    cefepime:  Var(MIC50): 1, MIC90: >32, RNG: (0.06–>32)
    cefotaxime:  Var(MIC50): 1, MIC90: >32, RNG: (0.03->32)
    cefotetan:  R(MIC50): >32, MIC90: >32, RNG: (2–>32)
    cefoxitin:  Var(MIC50): 8, MIC90: 64, RNG: (0.125–>128)
    ceftazidime:  R(MIC50): 32, MIC90: >64, RNG: (0.5–>64)
    azithromycin:  S(MIC50): 0.125, MIC90: 0.125, RNG: (0.125–0.25)
    erythromycin:  S(MIC50): 0.03, MIC90: 0.06, RNG: (0.03–0.125)
    clarithromycin:  Var(MIC50): ≤0.015->128), MIC90: Var(≤0.015->128
    quin-dalf:  S(MIC50): 0.25, MIC90: 0.5, RNG: (0.25-1)
    roxithromycin:  Var(MIC50): 0.25->128), MIC90: Var(0.25->128
    linezolid:  S(MIC50): 0.5, MIC90: 0.5, RNG: (0.5-0.5)
    levofloxacin:  R(MIC50): 8, MIC90: >8, RNG: (0.125–>8)
    moxifloxacin:  S(MIC50): 0.25, MIC90: 0.25, RNG: (0.06–0.5)
    Tetracyclines (μg/mL) Vancomycin Class (μg/mL) Polypep/ketides (μg/mL) Heterocycles (μg/mL) Other (μg/mL)
    doxycycline:  S(MIC50): 0.125, MIC90: 0.125, RNG: (0.125–0.25)
    minocycline:  S(MIC50): 0.03, MIC90: 0.06, RNG: (0.03–0.125)
    tetracycline:  S(MIC50): 4, MIC90: 4, RNG: (0.125–4)
    tigecycline:  SensRNG: (<0.015-1)
    dalbavancin:  S(MIC50): 0.25, MIC90: 1, RNG: (0.03–1)
    vancomycin:  S(MIC50): 0.5, MIC90: 0.5, RNG: (0.5-0.5)
    clindamycin:  R(MIC50): >8, MIC90: >8, RNG: (2–>8)
    daptomycin:  S(MIC50): 0.25, MIC90: 0.5, RNG: (0.125-0.5)

    References

    SPECIFIC REFERENCES FOR CORYNEBACTERIUM JEIKEIUM
  • Scanlan2012 - Gut dysbiosis in cystic fibrosis
  • Salipante2014 - Whole genome sequencing indicates Corynebacterium jeikeium comprises 4 separate genomospecies and identifies a dominant genomospecies among clinical isolates
  • Jackman1987 - Classification of corynebacteria associated with endocarditis (group JK) as Corynebacterium jeikeium sp. nov.
  • Tyrrell2012 - In vitro activity of TD-1792, a multivalent glycopeptide-cephalosporin antibiotic, against 377 strains of anaerobic bacteria and 34 strains of Corynebacterium species.
  • Goldstein2008 - In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
  • Goldstein2006a - In vitro activity of ceftobiprole against aerobic and anaerobic strains isolated from diabetic foot infections.
  • Goldstein2006b - In vitro activities of dalbavancin and 12 other agents against 329 aerobic and anaerobic gram-positive isolates recovered from diabetic foot infections.
  • Goldstein2000 - Comparative in vitro activities of GAR-936 against aerobic and anaerobic animal and human bite wound pathogens.
  • ...............................
    • GUT MICROBIOME COMPILATIONS AND METASTUDIES FOR CORYNEBACTERIUM JEIKEIUM
  • Zeller2014 - Potential of fecal microbiota for early-stage detection of colorectal cancer
  • ...............................
    • Added: September 19, 2022